Resistance training and rapamycin to enhance bone formation in postmenopausal women (STRONGBONE)

Conditions

General healthy elderly women with stable medical conditions

Brief summary

Percentage change in circulating levels of bone formation marker N-terminal fragment of procollagen type 1 (P1NP) at 24 weeks as compared with baseline

Detailed description

Change in circulating levels of bone turnover marker: C-terminal telopeptide of type 1 collagen (CTX) at baseline and 24 weeks, Changes in areal BMD at the lumbar spine (L1-4), total hip and femoral neck measured by dual energy x-ray absorptiometry DXA at baseline and 24 weeks, Changes in volumetric BMD, mass, bone microstructures and estimated strength at distal tibia and radius assessed using high resolution peripheral quantitative computed tomography (HRpQCT) at baseline and 24 weeks, Changes in muscle function, power and strength for upper and lower extremities will be assessed using, Changes in health-related quality of life assessment (SF-12 questionnaire)

Related papers

No related papers found yet.

Interventions

DRUGPLACEBO

DRUGEVEROLIMUS

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage change in circulating levels of bone formation marker N-terminal fragment of procollagen type 1 (P1NP) at 24 weeks as compared with baseline	—

Secondary

Measure	Time frame
Change in circulating levels of bone turnover marker: C-terminal telopeptide of type 1 collagen (CTX) at baseline and 24 weeks, Changes in areal BMD at the lumbar spine (L1-4), total hip and femoral neck measured by dual energy x-ray absorptiometry DXA at baseline and 24 weeks, Changes in volumetric BMD, mass, bone microstructures and estimated strength at distal tibia and radius assessed using high resolution peripheral quantitative computed tomography (HRpQCT) at baseline and 24 weeks, Changes in muscle function, power and strength for upper and lower extremities will be assessed using, Changes in health-related quality of life assessment (SF-12 questionnaire)	—

Measure

Time frame

Change in circulating levels of bone turnover marker: C-terminal telopeptide of type 1 collagen (CTX) at baseline and 24 weeks, Changes in areal BMD at the lumbar spine (L1-4), total hip and femoral neck measured by dual energy x-ray absorptiometry DXA at baseline and 24 weeks, Changes in volumetric BMD, mass, bone microstructures and estimated strength at distal tibia and radius assessed using high resolution peripheral quantitative computed tomography (HRpQCT) at baseline and 24 weeks, Changes in muscle function, power and strength for upper and lower extremities will be assessed using, Changes in health-related quality of life assessment (SF-12 questionnaire)

—

Countries

Denmark

Outcome results

None listed